Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 2/20 | 0.32 |
| ▸ | LAP3 | P28838 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27021681 | 0.77 | METAP1 (0.39) | METAP1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL21764561 | 0.77 | TSHR (0.39) | ALDH1A1 | |
| SCHEMBL24329091 | 0.76 | LAP3 (0.31) | ALDH1A1LAP3 | |
| SCHEMBL21764812 | 0.72 | CYP3A4 (0.47) | ALDH1A1 | |
| SCHEMBL21764724 | 0.71 | CYP3A4 (0.45) | METAP1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL2185473 | 0.71 | SMPD1 (0.49) | S1PR2S1PR1S1PR3S1PR4SMPD1 | |
| SCHEMBL3976301 | 0.71 | SMPD1 (0.49) | S1PR2S1PR1S1PR3S1PR4SMPD1 | |
| SCHEMBL2473811 | 0.70 | SMPD1 (0.50) | METAP1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL2471725 | 0.70 | METAP1 (0.48) | METAP1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL28389138 | 0.69 | METAP1 (0.44) | METAP1S1PR2S1PR1S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2022081594-A1 | ANTIMICROBIAL COMBINATION THERAPEUTICS | AEQUOR, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3474860-B1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | AEQUOR INC (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | AEQUOR, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | DDT, PFAS, DSTN | METAP1 556/4885S1PR2 2160/4885S1PR1 1868/4885 |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | DDT, AS3MT, GPX4 | METAP1 232/4885S1PR2 2000/4885S1PR1 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.